JP2025508051A - 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 - Google Patents

大うつ病性障害の治療に使用するためのアチカプラントの多形形態 Download PDF

Info

Publication number
JP2025508051A
JP2025508051A JP2024553358A JP2024553358A JP2025508051A JP 2025508051 A JP2025508051 A JP 2025508051A JP 2024553358 A JP2024553358 A JP 2024553358A JP 2024553358 A JP2024553358 A JP 2024553358A JP 2025508051 A JP2025508051 A JP 2025508051A
Authority
JP
Japan
Prior art keywords
aticaplant
crystalline form
atikaplant
amorphous
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553358A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508051A5 (cg-RX-API-DMAC7.html
Inventor
フェルナンデス,フィリップ
シュミット,マーク
ポポワ,ヴァニナ
サヴィッツ,アダム
メルコテ,ラマ
シー. ドレヴェツ,ワイン
ゴパール,シュリハリ
ペンバートン,ダレル
ラジシェティ,チャクラダール
ケジック,イヴァ
Original Assignee
ヤンセン ファーマシューティカルズ,インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカルズ,インコーポレーテッド filed Critical ヤンセン ファーマシューティカルズ,インコーポレーテッド
Publication of JP2025508051A publication Critical patent/JP2025508051A/ja
Publication of JP2025508051A5 publication Critical patent/JP2025508051A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024553358A 2022-03-07 2023-03-06 大うつ病性障害の治療に使用するためのアチカプラントの多形形態 Pending JP2025508051A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317475P 2022-03-07 2022-03-07
US63/317,475 2022-03-07
PCT/IB2023/052088 WO2023170550A1 (en) 2022-03-07 2023-03-06 Polymorph forms of aticaprant for use in treating major depressive disorder

Publications (2)

Publication Number Publication Date
JP2025508051A true JP2025508051A (ja) 2025-03-21
JP2025508051A5 JP2025508051A5 (cg-RX-API-DMAC7.html) 2026-03-05

Family

ID=85706849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553358A Pending JP2025508051A (ja) 2022-03-07 2023-03-06 大うつ病性障害の治療に使用するためのアチカプラントの多形形態

Country Status (14)

Country Link
US (3) US11998524B2 (cg-RX-API-DMAC7.html)
EP (1) EP4489747A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508051A (cg-RX-API-DMAC7.html)
KR (1) KR20240156409A (cg-RX-API-DMAC7.html)
CN (1) CN119156211A (cg-RX-API-DMAC7.html)
AU (1) AU2023232536A1 (cg-RX-API-DMAC7.html)
CA (1) CA3254365A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002627A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024012158A2 (cg-RX-API-DMAC7.html)
IL (1) IL315409A (cg-RX-API-DMAC7.html)
JO (1) JOP20240197A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010980A (cg-RX-API-DMAC7.html)
TW (1) TW202345796A (cg-RX-API-DMAC7.html)
WO (1) WO2023170550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
ES2189759T3 (es) 1999-05-12 2003-07-16 Hoffmann La Roche Derivados de imidazoiacepina.
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
PT2208727E (pt) 2002-09-19 2012-10-11 Lilly Co Eli Éteres diarílicos como antagonista do receptor opióide
WO2004080968A1 (en) 2003-03-07 2004-09-23 Eli Lilly And Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
EP1606275B1 (en) 2003-03-07 2008-08-27 Eli Lilly And Company Opioid receptor antagonists
CN1890208A (zh) 2003-12-12 2007-01-03 伊莱利利公司 类鸦片受体拮抗剂
BRPI0417714A (pt) 2003-12-22 2007-03-20 Lilly Co Eli composto, composição farmacêutica, e, uso de um composto
JP2007528898A (ja) 2004-03-12 2007-10-18 イーライ リリー アンド カンパニー オピオイド受容体拮抗物質
AU2005222640A1 (en) 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
US7381750B2 (en) 2004-03-12 2008-06-03 Eli Lilly And Company Amino-phenoxymethyl-benzamide opioid receptor antagonists
US7378448B2 (en) 2004-03-15 2008-05-27 Eli Lilly And Company Diphenylether amide derivatives as opioid receptor antagonists
WO2005090303A1 (en) 2004-03-15 2005-09-29 Eli Lilly And Company 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity
US8551986B2 (en) 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
PL2001456T3 (pl) 2006-04-04 2010-05-31 Emodys Gmbh Zastosowanie kompozycji zawierających antagonistę receptora opioidowego kappa do leczenia zaburzeń dysocjacyjnych
JP2010500372A (ja) 2006-08-09 2010-01-07 スミスクライン ビーチャム コーポレーション オピオイド受容体に対するアンタゴニストまたはインバースアゴニストとしての新規化合物
US8633175B2 (en) 2006-08-09 2014-01-21 Glaxosmithkline Llc Compounds as antagonists or inverse agonists at opioid receptors
MX2009002527A (es) 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
US7709522B2 (en) 2008-01-22 2010-05-04 Eli Lilly And Company Kappa selective opioid receptor antagonist
US20130303497A1 (en) 2010-08-05 2013-11-14 Conrig Pharma Aps Deuterated 5-ht1a receptor agonists
WO2013086496A2 (en) 2011-12-09 2013-06-13 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
US10377698B2 (en) 2015-03-30 2019-08-13 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and method for their production
WO2016191763A2 (en) 2015-05-28 2016-12-01 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
EP3490542A4 (en) 2016-07-26 2020-07-08 Flagship Pioneering Innovations V, Inc. NEUROMODULATION COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER BY MODULATION OF AN ANTI-CANCER RESPONSE
AU2017325870B2 (en) 2016-09-16 2021-07-22 Research Traingle Institute Tetrahydroisoquinoline kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
DK3596069T3 (da) 2017-03-17 2022-08-01 Scripps Research Inst Kappa-opioid-receptor-antagonister og produkter og fremgangsmåder relateret dertil
SG10201802129QA (en) 2017-07-05 2019-02-27 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
US11820835B2 (en) 2018-03-23 2023-11-21 University Of Kansas Cyclic tetrapeptide analogs
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
US11103171B2 (en) 2018-10-23 2021-08-31 BlackThor Therapeutics, Ine. Systems and methods for screening, diagnosing, and stratifying patients
US20200171025A1 (en) 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) * 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
WO2022234457A1 (en) * 2021-05-04 2022-11-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CA3254546A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. COMPOSITIONS CONTAINING ATICAPRANT
EP4489748A1 (en) 2022-03-07 2025-01-15 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant

Also Published As

Publication number Publication date
US20250325515A1 (en) 2025-10-23
CO2024012158A2 (es) 2024-09-30
US20230277499A1 (en) 2023-09-07
JOP20240197A1 (ar) 2024-09-05
TW202345796A (zh) 2023-12-01
US20240316003A1 (en) 2024-09-26
US12171743B2 (en) 2024-12-24
AU2023232536A1 (en) 2024-10-24
CN119156211A (zh) 2024-12-17
MX2024010980A (es) 2024-12-06
EP4489747A1 (en) 2025-01-15
CA3254365A1 (en) 2023-09-14
WO2023170550A1 (en) 2023-09-14
IL315409A (en) 2024-11-01
KR20240156409A (ko) 2024-10-29
US11998524B2 (en) 2024-06-04
CL2024002627A1 (es) 2025-01-24

Similar Documents

Publication Publication Date Title
US20250325515A1 (en) Forms Of Aticaprant
CN117771252A (zh) 神经活性甾类及其使用方法
CA3079259A1 (en) Ganaxolone for use in treating genetic epileptic disorders
JP7627963B2 (ja) テトラヒドロ-n,n-ジメチル-2,2-ジフェニル-3-フランメタンアミン(anavex2-73)のエナンチオマーならびにシグマ1レセプターにより調節されるアルツハイマー型および他の傷害の処置におけるその使用
JP2025508071A (ja) 純粋な形態の結晶質アチカプラント
JP2025508069A (ja) アチカプラントを含む組成物
AU2016370499B2 (en) Amorphous onapristone compositions and methods of making the same
DE69607904T2 (de) Potenzierung von Serotonin-Wirkstoffresponz
US12324796B2 (en) Sleep-improving compositions and methods of use
KR20150020160A (ko) 과민성 방광의 치료를 위한 무스카린 수용체 길항제 및 베타―3 아드레날린 수용체 작용제의 조합물
CN116514797A (zh) 美托哌丙嗪的新型多晶型形式
JP2016506918A (ja) イソメテプテン異性体
EA053068B1 (ru) Полиморфные формы атикапранта для применения при лечении большого депрессивного расстройства
JP2017141279A (ja) 網膜色素変性症(rp)を治療するための薬剤の製造のための化合物の使用
KR20260065892A (ko) 주요 우울 장애의 치료에 사용하기 위한 아티카프란트를 포함하는 조성물
JP2008127365A (ja) アレルギー性疾患の予防及び/又は治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260225